Literature DB >> 34880448

Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance.

Mari Mino-Kenudson1,2,3, Yin P Hung4,5,6, Daniel J Shepherd4,5, Elisabeth S Tabb4,5, Keiko Kunitoki7, M Lisa Zhang4,5, Marina Kem4, Jaimie Barth4, David A Qualls8,9, Meghan J Mooradian8,6, Justin F Gainor8,6.   

Abstract

Lymphocyte-activation gene 3 (LAG-3) modulates the tumor microenvironment through immunosuppressive effects. Its associations with clinicopathologic parameters and prognostic significance in non-small-cell lung carcinomas remain unclear. We examined LAG-3 expression in 368 resected non-small-cell lung carcinomas (including 218 adenocarcinomas and 150 squamous-cell carcinomas) using tissue microarrays, with normalization to CD8+ T-cell count (LAG-3/CD8 index), and correlated LAG-3, CD8, and LAG-3/CD8 index with clinicopathologic features, molecular status, and survival. LAG-3 expression in the immune cells (ranged 0.35-540.1 cells/mm²) was identified in 92% of non-small-cell lung carcinomas. In adenocarcinomas and squamous-cell carcinomas, LAG-3 expression correlated with CD8+ T-cell count and PD-L1 expression. In adenocarcinomas, high LAG-3 expression (defined as >median) was additionally associated with smoking history, high T stage, aggressive pathologic features (solid-predominant histologic pattern, lymphovascular invasion, and nodal metastasis), and lack of EGFR mutation. In the entire resected tumor cohort and in adenocarcinomas, high LAG-3 and LAG-3/CD8 index were each associated with worse overall survival. In squamous-cell carcinomas, high CD8 was associated with better overall survival. In an exploratory analysis of pretreatment samples from advanced non-small-cell lung carcinoma patients treated with pembrolizumab, high CD8 was predictive of improved overall and progression-free survival, while high LAG-3, but not high LAG-3/CD8 index, was associated with improved progression-free survival. In conclusion, the clinicopathologic correlations and prognostic impact of LAG-3 in non-small-cell lung carcinoma are histotype-dependent, highlighting differences in the immune microenvironment between adenocarcinomas and squamous-cell carcinomas. The predictive impact of LAG-3 warrants further investigation.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34880448      PMCID: PMC9050756          DOI: 10.1038/s41379-021-00974-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   8.209


  51 in total

Review 1.  PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.

Authors:  Sylvie Lantuejoul; Ming Sound-Tsao; Wendy A Cooper; Nicolas Girard; Fred R Hirsch; Anja C Roden; Fernando Lopez-Rios; Deepali Jain; Teh-Ying Chou; Noriko Motoi; Keith M Kerr; Yasushi Yatabe; Elisabeth Brambilla; John Longshore; Mauro Papotti; Lynette M Sholl; Erik Thunnissen; Natasha Rekhtman; Alain Borczuk; Lukas Bubendorf; Yuko Minami; Mary Beth Beasley; Johan Botling; Gang Chen; Jin-Haeng Chung; Sanja Dacic; David Hwang; Dongmei Lin; Andre Moreira; Andrew G Nicholson; Masayuki Noguchi; Giuseppe Pelosi; Claudia Poleri; William Travis; Akihiko Yoshida; Jillian B Daigneault; Ignacio I Wistuba; Mari Mino-Kenudson
Journal:  J Thorac Oncol       Date:  2019-12-20       Impact factor: 15.609

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

4.  Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.

Authors:  Khalid I Al-Shibli; Tom Donnem; Samer Al-Saad; Magnus Persson; Roy M Bremnes; Lill-Tove Busund
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

5.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

6.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 7.  The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer.

Authors:  Roy M Bremnes; Lill-Tove Busund; Thomas L Kilvær; Sigve Andersen; Elin Richardsen; Erna Elise Paulsen; Sigurd Hald; Mehrdad Rakaee Khanehkenari; Wendy A Cooper; Steven C Kao; Tom Dønnem
Journal:  J Thorac Oncol       Date:  2016-02-01       Impact factor: 15.609

8.  Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.

Authors:  M Lisa Zhang; Marina Kem; Meghan J Mooradian; Jean-Pierre Eliane; Tiffany G Huynh; A John Iafrate; Justin F Gainor; Mari Mino-Kenudson
Journal:  Mod Pathol       Date:  2018-10-26       Impact factor: 7.842

9.  Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Authors:  Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2015-02-03       Impact factor: 11.816

10.  Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.

Authors:  Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate
Journal:  EMBO Mol Med       Date:  2010-05       Impact factor: 12.137

View more
  1 in total

Review 1.  LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors.

Authors:  Natalia Sauer; Wojciech Szlasa; Laura Jonderko; Małgorzata Oślizło; Dominika Kunachowicz; Julita Kulbacka; Katarzyna Karłowicz-Bodalska
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.